Malhi GS, Mann JJ. Depression. Lancet. 2018;392(10161):2299–312. https://doi.org/10.1016/S0140-6736(18)31948-2.
de Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA. 1998;95(1):322–7. https://doi.org/10.1073/pnas.95.1.322.
Article PubMed PubMed Central Google Scholar
Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998;92(4):573–85. https://doi.org/10.1016/s0092-8674(00)80949-6.
Article CAS PubMed Google Scholar
Fronczek R, Lammers GJ, Balesar R, et al. The number of hypothalamic hypocretin (orexin) neurons is not affected in Prader-Willi syndrome. J Clin Endocrinol Metab. 2005;90(9):5466–70. https://doi.org/10.1210/jc.2005-0296.
Article CAS PubMed Google Scholar
Peyron C, Tighe DK, van den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci. 1998;18(23):9996–10015. https://doi.org/10.1523/JNEUROSCI.18-23-09996.1998.
Article CAS PubMed PubMed Central Google Scholar
Marcus JN, Aschkenasi CJ, Lee CE, et al. Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol. 2001;435(1):6–25. https://doi.org/10.1002/cne.1190.
Article CAS PubMed Google Scholar
Chieffi S, Carotenuto M, Monda V, et al. Orexin system: the key for a healthy life. Front Physiol. 2017;8:357. https://doi.org/10.3389/fphys.2017.00357.
Article PubMed PubMed Central Google Scholar
Tsujino N, Sakurai T. Role of orexin in modulating arousal, feeding, and motivation. Front Behav Neurosci. 2013;7:28. https://doi.org/10.3389/fnbeh.2013.00028.
Article CAS PubMed PubMed Central Google Scholar
Mahler SV, Moorman DE, Smith RJ, et al. Motivational activation: a unifying hypothesis of orexin/hypocretin function. Nat Neurosci. 2014;17(10):1298–303. https://doi.org/10.1038/nn.3810.
Article CAS PubMed PubMed Central Google Scholar
Nollet M, Leman S. Role of orexin in the pathophysiology of depression: potential for pharmacological intervention. CNS Drugs. 2013;27(6):411–22. https://doi.org/10.1007/s40263-013-0064-z.
Article CAS PubMed Google Scholar
Khairuddin S, Aquili L, Heng BC, et al. Dysregulation of the orexinergic system: a potential neuropeptide target in depression. Neurosci Biobehav Rev. 2020;118:384–96. https://doi.org/10.1016/j.neubiorev.2020.07.040.
Article CAS PubMed Google Scholar
Feng P, Vurbic D, Wu Z, et al. Changes in brain orexin levels in a rat model of depression induced by neonatal administration of clomipramine. J Psychopharmacol. 2008;22(7):784–91. https://doi.org/10.1177/0269881106082899.
Article CAS PubMed PubMed Central Google Scholar
Nocjar C, Zhang J, Feng P, et al. The social defeat animal model of depression shows diminished levels of orexin in mesocortical regions of the dopamine system, and of dynorphin and orexin in the hypothalamus. Neuroscience. 2012;218:138–53. https://doi.org/10.1016/j.neuroscience.2012.05.033.
Article CAS PubMed Google Scholar
Arendt DH, Ronan PJ, Oliver KD, et al. Depressive behavior and activation of the orexin/hypocretin system. Behav Neurosci. 2013;127(1):86–94. https://doi.org/10.1037/a0031442.
Article CAS PubMed Google Scholar
Kim TK, Kim JE, Park JY, et al. Antidepressant effects of exercise are produced via suppression of hypocretin/orexin and melanin-concentrating hormone in the basolateral amygdala. Neurobiol Dis. 2015;79:59–69. https://doi.org/10.1016/j.nbd.2015.04.004.
Article CAS PubMed Google Scholar
Jalewa J, Wong-Lin K, McGinnity TM, et al. Increased number of orexin/hypocretin neurons with high and prolonged external stress-induced depression. Behav Brain Res. 2014;272:196–204. https://doi.org/10.1016/j.bbr.2014.05.030.
Article CAS PubMed Google Scholar
Rainero I, Ostacoli L, Rubino E, et al. Association between major mood disorders and the hypocretin receptor 1 gene. J Affect Disord. 2011;130(3):487–91. https://doi.org/10.1016/j.jad.2010.10.033.
Article CAS PubMed Google Scholar
Cengiz M, Karaj V, Kocabasoğlu N, et al. Orexin/hypocretin receptor, Orx1, gene variants are associated with major depressive disorder. Int J Psychiatry Clin Pract. 2019;23(2):114–21. https://doi.org/10.1080/13651501.2018.1551549.
Article CAS PubMed Google Scholar
Brundin L, Björkqvist M, Petersén A, et al. Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder. Eur Neuropsychopharmacol. 2007;17(9):573–9. https://doi.org/10.1016/j.euroneuro.2007.01.005.
Article CAS PubMed Google Scholar
Brundin L, Björkqvist M, Träskman-Bendz L, et al. Increased orexin levels in the cerebrospinal fluid the first year after a suicide attempt. J Affect Disord. 2009;113(1–2):179–82. https://doi.org/10.1016/j.jad.2008.04.011.
Article CAS PubMed Google Scholar
Salomon RM, Ripley B, Kennedy JS, et al. Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects. Biol Psychiatry. 2003;54(2):96–104. https://doi.org/10.1016/s0006-3223(02)01740-7.
Article CAS PubMed Google Scholar
Pålhagen S, Qi H, Mårtensson B, et al. Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson’s disease and major depression. J Neurol. 2010;257(4):524–32. https://doi.org/10.1007/s00415-009-5353-6.
Article CAS PubMed Google Scholar
Schmidt FM, Brügel M, Kratzsch J, et al. Cerebrospinal fluid hypocretin-1 (orexin A) levels in mania compared to unipolar depression and healthy controls. Neurosci Lett. 2010;483(1):20–2. https://doi.org/10.1016/j.neulet.2010.07.038.
Article CAS PubMed Google Scholar
Schmidt FM, Arendt E, Steinmetzer A, et al. CSF-hypocretin-1 levels in patients with major depressive disorder compared to healthy controls. Psychiatry Res. 2011;190(2–3):240–3. https://doi.org/10.1016/j.psychres.2011.06.004.
Article CAS PubMed Google Scholar
Winrow CJ, Renger JJ. Discovery and development of orexin receptor antagonists as therapeutics for insomnia. Br J Pharmacol. 2014;171(2):283–93. https://doi.org/10.1111/bph.12261.
Article CAS PubMed Google Scholar
Herring WJ, Snyder E, Budd K, et al. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology. 2012;79(23):2265–74. https://doi.org/10.1212/WNL.0b013e31827688ee.
Article CAS PubMed Google Scholar
Michelson D, Snyder E, Paradis E, et al. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13(5):461–71. https://doi.org/10.1016/S1474-4422(14)70053-5.
Article CAS PubMed Google Scholar
Herring WJ, Connor KM, Ivgy-May N, et al. Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials. Biol Psychiatry. 2016;79(2):136–48. https://doi.org/10.1016/j.biopsych.2014.10.003.
Article CAS PubMed Google Scholar
Herring WJ, Connor KM, Snyder E, et al. Suvorexant in patients with insomnia: pooled analyses of three-month data from phase-3 randomized controlled clinical trials. J Clin Sleep Med. 2016;12(9):1215–25. https://doi.org/10.5664/jcsm.6116.
Article PubMed PubMed Central Google Scholar
Murphy P, Moline M, Mayleben D, et al. Lemborexant, a dual orexin receptor antagonist (DORA) for the treatment of insomnia disorder: results from a bayesian, adaptive, randomized, double-blind, placebo-controlled study. J Clin Sleep Med. 2017;13(11):1289–99. https://doi.org/10.5664/jcsm.6800.
Article PubMed PubMed Central Google Scholar
Rosenberg R, Murphy P, Zammit G, et al. Comparison of lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder: a phase 3 randomized clinical trial. JAMA Netw Open. 2019;2(12):e1918254. https://doi.org/10.1001/jamanetworkopen.2019.
Article PubMed PubMed Central Google Scholar
Yardley J, Kärppä M, Inoue Y, et al. Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: results from a phase 3 randomized clinical trial. Sleep Med. 2021;80:333–42. https://doi.org/10.1016/j.sleep.2021.01.048.
Zammit G, Dauvilliers Y, Pain S, et al. Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder. Neurology. 2020;94(21):e2222–32. https://doi.org/10.1212/WNL.0000000000009475.
Article CAS PubMed Google Scholar
Xue T, Wu X, Chen S, et al. The efficacy and safety of dual orexin receptor antagonists in primary insomnia: a systematic review and network meta-analysis. Sleep Med Rev. 2022;61: 101573. https://doi.org/10.1016/j.smrv.2021.101573.
Article CAS PubMed Google Scholar
Kan CC, Breteler MH, Zit
留言 (0)